New ultrasound technique could spare infants from invasive brain monitoring
NCT ID NCT06693752
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests whether a special ultrasound with a contrast dye can safely and effectively measure brain health in infants with hydrocephalus, a condition where fluid builds up in the brain. About 20 infants under 1.5 years old will receive an injection of the contrast agent through an IV, followed by an ultrasound. The goal is to see if this method can replace or reduce the need for invasive pressure monitors and shunts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sulfur hexafluoride lipid-type A microspheres (contrast agent)
- What this could lead to
- If successful, this could lead to a safer, non-invasive way to monitor brain pressure and blood flow in infants with hydrocephalus, reducing reliance on invasive shunts.
- What could go wrong
- This is a small pilot study with only 20 infants, so results may not apply to all cases. The contrast agent also carries a small risk of allergic reactions or side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYDROCEPHALUS ACQUIRED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.